Oruka Therapeutics

ORKANasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$5.960 B

$98.82 +0.41%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$105.4M

Loss-making

Shares outstanding

60,312,101

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#1Idexx LaboratoriesIDXX$46.2B
#2LantheusLNTH$6.57B
#3Oruka TherapeuticsORKA$5.96B
#4Celldex TherapeuticsCLDX$3.27B
#5NeogenNEOG$2.50B

Where these numbers come from

Share counts and financials for Oruka Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.